Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more
Lasa Supergenerics Limited (LASA) - Total Liabilities
Latest total liabilities as of September 2025: ₹152.61 Million INR
Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has total liabilities worth ₹152.61 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lasa Supergenerics Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lasa Supergenerics Limited Competitors by Total Liabilities
The table below lists competitors of Lasa Supergenerics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bless Asset Group PCL
BK:BLESS
|
Thailand | ฿1.07 Billion |
|
PT Trimuda Nuansa Citra Tbk
JK:TNCA
|
Indonesia | Rp7.06 Billion |
|
Venerable Ventures Ltd
V:VLV
|
Canada | CA$601.43K |
|
Canadian Metals Inc
PINK:CNMTF
|
USA | $1.85 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Lasa Supergenerics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.03 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lasa Supergenerics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual total liabilities of Lasa Supergenerics Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹178.19 Million | -67.12% |
| 2024-03-31 | ₹541.92 Million | +18.92% |
| 2023-03-31 | ₹455.69 Million | -11.15% |
| 2022-03-31 | ₹512.87 Million | +4.79% |
| 2021-03-31 | ₹489.43 Million | -45.93% |
| 2020-03-31 | ₹905.23 Million | -40.91% |
| 2019-03-31 | ₹1.53 Billion | -9.59% |
| 2018-03-31 | ₹1.69 Billion | +10.92% |
| 2017-03-31 | ₹1.53 Billion | -- |